RNS Number : 6629U MaxCyte, Inc. 02 August 2022 MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights Rockville, MD - 2 August 2022 : MaxCyte (LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform technologies to advance
RNS Number : 1318T MaxCyte, Inc. 20 July 2022 Change of Registered Office GAITHERSBURG, MD , July 20, 2022 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based
RNS Number : 6595S MaxCyte, Inc. 15 July 2022 MaxCyte to Report Second Quarter 2022 Financial Results on August 10, 2022 GAITHERSBURG, MD , July 15, 2022 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform
GAITHERSBURG, Md., July 15, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery,
LG Chem to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to accelerate the development of its T-cell therapy candidates for solid tumors GAITHERSBURG, Md., July 12, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading commercial cell-engineering company
RNS Number : 1712S MaxCyte, Inc. 12 July 2022 MaxCyte Signs Strategic Platform License with LG Chem to Advance its Allogeneic CAR-T Programs LG Chem to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to
RNS Number : 0898S MaxCyte, Inc. 12 July 2022 MaxCyte, Inc. (" MaxCyte " or the "Company") Grant of Options Gaithersburg, Maryland - 12 July 2022 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), the global clinical-stage cell-based therapies and life sciences company, announces that on 29 June
RNS Number : 9121R MaxCyte, Inc. 08 July 2022 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing
RNS Number : 9281Q MaxCyte, Inc. 01 July 2022 MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights Gaithersburg, Maryland - 1 July 2022 : MaxCyte (LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform technologies to advance
RNS Number : 7279Q MaxCyte, Inc. 30 June 2022 Result of AGM GAITHERSBURG, MD , June 30, 2022 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as
